Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC).

REGN-EB3 was one of several experimental therapies considered for the treatment of Ebola during the current outbreak by a scientific panel at a May 17 meeting. The therapies were evaluated under the World Health Organization's Monitored Emergency Use of Unregistered Interventions (MEURI) framework. The panel concluded that available data on REGN-EB3 are "very promising" and supported its use in settings where Zmapp and remdesivir (GS-5734) are not available. ...